本文關(guān)鍵詞：基于研發(fā)和市場(chǎng)的中藥現(xiàn)代化戰(zhàn)略研究，，由筆耕文化傳播整理發(fā)布。

        中藥作為中華民族的瑰寶,正日益得到世界的關(guān)注。中藥領(lǐng)域作為我國少數(shù)具有國際優(yōu)勢(shì)的領(lǐng)域之一,已成為制藥行業(yè)共同矚目的問題。我國在30年前就提出中藥現(xiàn)代化,到20世紀(jì)90年代中后期,形成真正意義上的“中藥現(xiàn)代化”的概念和規(guī)范。中藥現(xiàn)代化是指將傳統(tǒng)中藥的優(yōu)勢(shì)特色與現(xiàn)代化科學(xué)技術(shù)相結(jié)合,指導(dǎo)中藥的研究、開發(fā)、生產(chǎn)、管理和應(yīng)用,以適應(yīng)社會(huì)發(fā)展需求的過程。中藥現(xiàn)代化是中醫(yī)藥現(xiàn)代化的重要組成部分,也是中醫(yī)藥事業(yè)發(fā)展的重點(diǎn)領(lǐng)域之一。在推行中藥現(xiàn)代化戰(zhàn)略發(fā)展的30年期間,我國中藥產(chǎn)業(yè)取得了顯著的成就,但是隨著健康觀念、醫(yī)學(xué)模式的轉(zhuǎn)變和科學(xué)技術(shù)的進(jìn)步,中藥發(fā)展環(huán)境發(fā)生了深刻變化,如今正面臨著新的發(fā)展機(jī)遇和來自全球化競(jìng)爭(zhēng)的嚴(yán)峻挑戰(zhàn)。如何抓住機(jī)遇、應(yīng)對(duì)挑戰(zhàn)、制定對(duì)策,推動(dòng)我國中藥領(lǐng)域健康、與時(shí)俱進(jìn)的發(fā)展,提高中藥領(lǐng)域研發(fā)的整體水平和國際化競(jìng)爭(zhēng)力,將成為我國“十二五”規(guī)劃中有關(guān)中藥產(chǎn)業(yè)發(fā)展亟待解決的問題。本文在對(duì)國內(nèi)外有關(guān)中藥現(xiàn)代化的研究成果進(jìn)行整理分析的基礎(chǔ)上,提出了對(duì)中藥和中藥現(xiàn)代化概念的新看法,并結(jié)合中藥現(xiàn)代化面臨的國內(nèi)外環(huán)境,如疾病譜和醫(yī)學(xué)模式的變化、全球化競(jìng)爭(zhēng)日益激烈、天然藥物市場(chǎng)的擴(kuò)張以及國內(nèi)新醫(yī)改給醫(yī)藥企業(yè)帶來的影響等,對(duì)中藥現(xiàn)代化戰(zhàn)略進(jìn)行了細(xì)致分析,從一個(gè)新視角來重新審視中藥現(xiàn)代化發(fā)展戰(zhàn)略。在基于系統(tǒng)理論的基礎(chǔ)上運(yùn)用動(dòng)態(tài)比較優(yōu)勢(shì)得出中藥研發(fā)和市場(chǎng)開拓是兩個(gè)關(guān)鍵戰(zhàn)略問題,繼而分別采用產(chǎn)業(yè)戰(zhàn)略管理分析方法——SWOT分析法進(jìn)行了戰(zhàn)略分析,并做出戰(zhàn)略選擇。1.中藥現(xiàn)代化是充分發(fā)揮科技的作用,繼承和創(chuàng)新并重,將傳統(tǒng)中醫(yī)藥的優(yōu)勢(shì)、特色與現(xiàn)代科學(xué)技術(shù)相結(jié)合,提升企業(yè)的研發(fā)能力與核心競(jìng)爭(zhēng)力。然而,實(shí)現(xiàn)以上戰(zhàn)略目標(biāo)的核心任務(wù)就是研制、開發(fā)出一批服用方便、藥效明確、質(zhì)量可靠的現(xiàn)代中藥投放市場(chǎng)。我國在中藥研發(fā)中具有得天獨(dú)厚的藥材、人才與科研資源優(yōu)勢(shì)；深厚的中醫(yī)藥文化積淀、理論內(nèi)容與實(shí)踐積累是我國發(fā)展中醫(yī)藥不可復(fù)制的競(jìng)爭(zhēng)力。但是目前制約中藥研發(fā)進(jìn)展的因素也不容忽視,例如,資源的整合不夠完善,科研院所、高校資源與企業(yè)聯(lián)系不緊密；中醫(yī)藥的研究平臺(tái)尚不完善,匯集多學(xué)科人才,多學(xué)科碰撞、交融的創(chuàng)新平臺(tái)尚未建立；很多企業(yè)對(duì)于中藥研發(fā)仍重視不夠,無論是政府支持還是企業(yè)自主研發(fā)的資金投入都還很不足；中醫(yī)藥基礎(chǔ)研究不足成為中藥研發(fā)的瓶頸等。除了內(nèi)部的優(yōu)勢(shì)與劣勢(shì)問題,還應(yīng)關(guān)注中藥研發(fā)的外部環(huán)境。規(guī)避中藥資源的日益減少,知識(shí)產(chǎn)權(quán)流失等威脅的同時(shí),抓住外部機(jī)會(huì),借鑒國際研發(fā)新技術(shù)促進(jìn)我國中藥研發(fā)；以與化學(xué)藥的相對(duì)優(yōu)勢(shì)來發(fā)展中藥市場(chǎng),研發(fā)國際熱衷消費(fèi)的中藥養(yǎng)生、保健、化妝品等。2.市場(chǎng)是企業(yè)實(shí)現(xiàn)其價(jià)值的場(chǎng)所,企業(yè)服務(wù)于市場(chǎng),它的存在就是為了滿足市場(chǎng)的需求,失去了市場(chǎng),企業(yè)也就不會(huì)存在。中藥市場(chǎng)面臨諸多發(fā)展空間,隨著人類社會(huì)的發(fā)展以及生活水平逐漸提高,人們對(duì)健康的關(guān)注程度日益加大,現(xiàn)代醫(yī)學(xué)也更加注重對(duì)人體的整體調(diào)節(jié)作用,保持機(jī)體的陰陽平衡。同時(shí),中藥產(chǎn)品具有諸多方面化學(xué)藥無法比擬的優(yōu)勢(shì),如豐富而又古老的中醫(yī)藥治療理論、中藥產(chǎn)品安全低毒有效的特性以及中藥產(chǎn)品在惡性腫瘤、心腦血管病、老年性疾病和病毒性疾病等疑難雜癥方面所具有的獨(dú)特療效。中藥的這些特點(diǎn),無疑更加符合現(xiàn)代人日常保健的需求,天然藥物產(chǎn)品在西方國家越來越受歡迎便是一個(gè)充分的證明；我國新醫(yī)改將中藥產(chǎn)品納入基本藥物目錄以及全球人口老齡化的不斷加劇,也無疑為中藥產(chǎn)品提供了一片廣闊的市場(chǎng)。然而,我國中藥產(chǎn)業(yè)同時(shí)也面臨不利的一面,國內(nèi)制藥產(chǎn)業(yè)的產(chǎn)品質(zhì)量問題一直是企業(yè)難以跨越的一道鴻溝；此外,不少知名跨國制藥企業(yè)已經(jīng)開始瓜分這一蛋糕,歐美國家為遏制他國的中藥產(chǎn)業(yè)的發(fā)展也制定了各種嚴(yán)格的貿(mào)易壁壘和技術(shù)壁壘,嚴(yán)重阻礙了國內(nèi)中藥企業(yè)市場(chǎng)地拓展。中藥現(xiàn)代化發(fā)展必須在充分利用機(jī)會(huì)和優(yōu)勢(shì),規(guī)避風(fēng)險(xiǎn)和劣勢(shì)的前提下進(jìn)行戰(zhàn)略選擇。然而,戰(zhàn)略還需要政府和企業(yè)政策措施的保障才能得以有效實(shí)施和貫徹,中藥產(chǎn)業(yè)現(xiàn)代化戰(zhàn)略實(shí)施的重要保障措施包括：加強(qiáng)中藥基礎(chǔ)研究,加強(qiáng)中藥知識(shí)產(chǎn)權(quán)保護(hù),加強(qiáng)人才培養(yǎng)和教育,培育國內(nèi)傳統(tǒng)中藥產(chǎn)業(yè)市場(chǎng),加強(qiáng)國際傳統(tǒng)醫(yī)藥的開發(fā)利用,選擇中藥企業(yè)集團(tuán)培育中藥跨國公司,發(fā)揮政府在應(yīng)對(duì)國際貿(mào)易壁壘中的作用。

    As a treasure of Chinese, Traditional Chinese Medicine (TCM) is getting the world’s attention increasingly. As one of China’s few areas with the international strength, Chinese medicine field has become a common attention in the pharmaceutical industry.30 years ago, China proposed the development of the modernization of TCM, but until the mid to late 90s of the 20th century, the concept and specifications of " modernization of TCM " had been formed at a real sense. Modernization of TCM refers to using modern science and technology, combined with the advanced characteristics of TCM, to guide the research, development, production, management and applications of the Chinese medicine, to meet the demand of social development. Modernization of TCM is an important part of Modernization of Chinese medicine, but also is a focus area of the pharmaceutical industry development. In the 30-year period of implementation of TCM Modernization strategic, Chinese medicine industry has made significant achievements. But as the concept of health and medical model is changing and the science and technology is processing, the development environment of TCM has being undergone profound changes, and now is facing lots of new opportunities and challenges from global competition. How to seize opportunities, meet challenges and develop strategies to promote the healthy development of Chinese medicine field, and how to improve the overall level of R & D and international competitiveness of Chinese medicine field, will become the problems to be solved of the China’s "Twelfth Five-Year Plan" of Chinese medicine industry development.In this paper, based on the analysis of research results of the modernization of TCM at home and abroad, some new ideas about concepts of the modernization of TCM and Chinese medicine have been put forward. Then combining with internal and external environment of the modernization of TCM is facing, such as changes in disease spectrum and the medical model, increasingly fierce global competition, the expansion of natural medicine market and the impact of domestic new health care reform on pharmaceutical enterprises, the strategy of modernization TCM has been analyzed at great length, and from a new perspective the development strategy of modernization of TCM also has been re-examined. Based on the system theory, two key strategic issues which are TCM’s R & D and market development has been derived by using the theory of dynamic comparative advantage. And then strategic analysis and strategic choice has been made by the industry strategic management approach-SWOT analysis.Modernization of Chinese medicine is to give full play of science and technology. pay equal attention. to both inheritance and innovation, unite the advantages and features of TCM together with modern science and technology, enhance corporate R & D capability and core competitiveness. However, in order to achieve the core strategic goals, companies should research and develop a number of modern medicine and then put on the market, they are easy taken, with clear efficacy and reliable quality, in China,R & D in Chinese medicine has exceptional advantage in medicinal materials,talents and research resources; what’s more,profound cultural heritage,theory and practice accumulation of Chinese medicine is our country’s core competitiveness which cannot be copied. But now the factors restricting the progress of Chinese medicine research and development cannot be ignored, for example, the integration of resources is not perfect, research institutes, university resources do not contact enough closely with companies; the innovative platform of Chinese medicine of bringing together multidisciplinary professionals, multidisciplinary impact and blend has not been established; many companies do not place enough emphasis for Chinese medicine research and development, whether the government support or company’s independent R&D funding are both inadequate; and lacking of basic research is now a bottlenecks in Chinese medicine research and development.In addition to internal strengths and weaknesses, we should focus on the external environment of Chinese medicine R & D. one side, Circumvent the threats’of TCM resources dwindling and the loss of intellectual property rights, the other side, seize external opportunities, borrow ideas from international new technologies for TCM research and development; take the comparative advantages of chemical drugs to develop the market of Chinese medicine, research and develop products which international like to consume for nourishing of life, health care and cosmetic.Market is the most important thing for all companies, and the companies achieve its value in the market. All companies depend on the market. Without of the market, all companies would not exist. Therefore, to seize the opportunity form the market, it is of great importance for Chinese companies to analyze the TCM market before they make their market strategy. With the development of society and the increasing of the people’s quality of life, our human has pay more and more attention on our healthy, and modern medical also has pay more attention on the overall regulation of the human body to maintain the body’s yin and yang balance. Compared with the chemical drug, the TCM has many aspects of advantage, such as the ancient and useful TCM theory, high safety and low toxicity, and it unique effect in cancer, cardiovascular, cerebrovascular disease, senile diseases, viral diseases and other incurable diseases. It is no doubt that these features of TCM are in accordance with our daily life. What’s more, the Chinese new medical reform has channel the TCM into the basic drug list, and the Growing aging population also has provide a vast market to the TCM company. However, our drug industry still face some challenge. First, the quality of some TCM is not stable. Second, many well-known multinational pharmaceutical companies have begun to research the botanicals. In addition, the Europe and the United States have developed a variety of stringent trade barriers and technical barriers to restrict Chinese drug industry.However the effective implementation of the strategy also requires government’s and corporation’s policies and measures. Based on the SWOT analysis of the modernization of Chinese medicine industry in China, some feasible specific strategies have been put forward, such as strengthening the basic research of Chinese medicine, strengthening the intellectual property protection of traditional Chinese medicine, strengthening the personnel training and education, fostering domestic markets of TCM industry, strengthening the international development and utilization of traditional medicine, choosing some enterprise groups to cultivate Chinese medicine multinational companies, and dealing with international trade barriers effectively by the government.

基于研發(fā)和市場(chǎng)的中藥現(xiàn)代化戰(zhàn)略研究

摘要10-12Abstract12-15第1章 緒論16-35    1.1 研究背景16-26    1.2 我國中藥現(xiàn)代化研究現(xiàn)狀26-30    1.3 研究目的及意義30-31    1.4 研究內(nèi)容31-32    1.5 研究思路32-33    1.6 研究方法33-35第2章 基礎(chǔ)概念與理論基礎(chǔ)35-48    2.1 中藥現(xiàn)代化相關(guān)概念35-40    2.2 相關(guān)理論40-48第3章 基于研發(fā)和市場(chǎng)的中藥現(xiàn)代化戰(zhàn)略問題的提出48-54    3.1 中藥現(xiàn)代化戰(zhàn)略提出的必要性48-50    3.2 中藥現(xiàn)代化系統(tǒng)50-51    3.3 中藥現(xiàn)代化優(yōu)勢(shì)難以發(fā)揮的關(guān)鍵障礙51-54第4章 基于研發(fā)的中藥現(xiàn)代化戰(zhàn)略54-68    4.1 中藥研發(fā)概述54-57    4.2 中藥研發(fā)環(huán)境的SWOT分析57-64    4.3 基于研發(fā)的中藥現(xiàn)代化SWOT戰(zhàn)略匹配與選擇64-68第5章 基于市場(chǎng)拓展的中藥現(xiàn)代化戰(zhàn)略68-97    5.1 國外中藥產(chǎn)品市場(chǎng)概況68-75    5.2 中藥產(chǎn)品市場(chǎng)拓展的SWOT分析75-93    5.3 基于市場(chǎng)的中藥現(xiàn)代化戰(zhàn)略匹配與選擇93-97第6章 對(duì)建立中藥現(xiàn)代化戰(zhàn)略實(shí)施保障措施的建議97-108    6.1 重視中藥基礎(chǔ)研究97-99    6.2 重視對(duì)中藥知識(shí)產(chǎn)權(quán)的保護(hù)99-100    6.3 加強(qiáng)中藥人才培養(yǎng)和教育100-102    6.4 中藥重點(diǎn)產(chǎn)品的市場(chǎng)培育102-104    6.5 選擇中藥龍頭企業(yè)培育中藥跨國公司104-105    6.6 發(fā)揮政府在應(yīng)對(duì)國際貿(mào)易壁壘中的作用105-108第7章 結(jié)論108-110參考文獻(xiàn)110-117致謝117-118個(gè)人簡歷118-151

  本文關(guān)鍵詞：基于研發(fā)和市場(chǎng)的中藥現(xiàn)代化戰(zhàn)略研究，由筆耕文化傳播整理發(fā)布。